Melinta Therapeutics, Inc. (MLNT), a commercial-stage company focused on the development and commercialization of novel antibiotics to treat serious bacterial infections, today announced that Jennifer Sanfilippo has been named interim chief executive officer and director, effective August 28, 2019. Prior to this appointment, Ms. Sanfilippo served as senior vice president and general counsel of Melinta. “Jennifer’s appointment to interim chief executive officer is the result of a thoughtful succession planning process undertaken by the board of directors.
Melinta Therapeutics, Inc. (the “Company” or “Melinta”), a commercial-stage company focused on the development and commercialization of novel antibiotics to treat serious bacterial infections, confirmed today that the Company’s agreement with funds managed by Deerfield Management Company, L.P., the lenders under the Company’s senior credit facility (“Deerfield”), has been designated as the highest and best offer for the Company and its assets following the completion of a formal marketing process. The auction scheduled for March 6, 2020 will not proceed, as no party submitted a higher and better bid in accordance with the bidding procedures established by the United States Bankruptcy Court for the District of Delaware (the “Court”).
52 Presentations by Coalition Members During the Annual Meeting WASHINGTON , Oct. 1, 2019 /PRNewswire/ -- The Antimicrobials Working Group (AWG), a coalition of companies with the mission to combat drug-resistant ...
Companies in the news are: AMZN, BOOM, RMD, MLNT
Investors need to pay close attention to Melinta Therapeutics (MLNT) stock based on the movements in the options market lately.
September turned out to be a fruitful month for FDA approvals. The regulatory agency gave its nod to Ardelyx Inc (NASDAQ: ARDX )'s Ibsrela, a new molecular entity indicated to treat irritable bowel syndrome ...
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs Nov. 13.) Antares Pharma Inc (NASDAQ: ATRS ) Arrowhead Pharmaceuticals ...
A look at the shareholders of Melinta Therapeutics, Inc. (NASDAQ:MLNT) can tell us which group is most powerful...
Melinta Therapeutics, Inc. (MLNT) delivered earnings and revenue surprises of 10.88% and 2.35%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. We have processed the filings of the more than 700 world-class investment firms that we track and now have access to the collective wisdom contained in […]
One of the biggest stories of last week was how Melinta Therapeutics, Inc. (NASDAQ:MLNT) shares plunged 36% in the...
Biotech stocks saw some strength last week. Positive clinical readouts, a couple of M&A deals and hopes of drug companies clinching a broader opioid settlement agreement worked in favor of the sector. ...
Melinta Therapeutics, Inc. (MLNT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Melinta Therapeutics, Inc. (MLNT), a commercial-stage company focused on the development and commercialization of novel antibiotics to treat serious bacterial infections, today announced the U.S. Food and Drug Administration (FDA) has approved BAXDELA® (delafloxacin) for the treatment of adult patients with community-acquired bacterial pneumonia (CABP) caused by designated susceptible bacteria. This supplemental approval follows FDA priority review based on the previous Qualified Infectious Disease Product (QIDP) designation, which provides certain incentives for the development of antibacterial and antifungal treatments for serious or life-threatening infections.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Sept. 3) Ardelyx Inc (NASDAQ: ARDX ) ( reported positive results ...
It is not uncommon to see companies perform well in the years after insiders buy shares. The flip side of that is that...
Melinta Therapeutics, Inc. (MLNT) (the “Company” or “Melinta”), a commercial-stage company focused on the development and commercialization of novel antibiotics to treat serious bacterial infections, today announced that it has entered into a Restructuring Support Agreement (the “Agreement”) with the lenders under its senior credit facility, Deerfield Private Design Fund III, L.P. and Deerfield Private Design Fund IV, L.P. (the “Supporting Lenders”). Under the Agreement, the Supporting Lenders would acquire the Company as a going concern by exchanging $140 million of secured claims arising under its senior credit facility for 100 percent of the equity to be issued by the reorganized Company pursuant to a pre-negotiated chapter 11 plan of reorganization.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Oct. 24) AstraZeneca plc (NYSE: AZN ) (reacted to a beat-and-raise ...
Melinta Therapeutics, Inc. (the “Company” or “Melinta”), a commercial-stage company focused on the development and commercialization of novel antibiotics to treat serious bacterial infections, today announced that on February 11, 2020, the United States Bankruptcy Court for the District of Delaware (the “Court”) entered an order approving Melinta’s proposed bidding procedures and Chapter 11 sale process timeline (the “Bidding Procedures Order”), thereby establishing a framework for the near-term acquisition and continuation of Melinta’s business as a going concern. The Bidding Procedures Order was entered with the consent of the major constituents in Melinta’s Chapter 11 cases, following extensive negotiations among them to achieve consensus concerning the framework for Melinta’s sale process.
Melinta Therapeutics, Inc. (MLNT), a commercial-stage company focused on the development and commercialization of novel antibiotics to treat serious bacterial infections, today announced that it has filed its quarterly report on Form 10-Q for the three and nine months ended September 30, 2019 with the Securities and Exchange Commission (“SEC”). The Company encourages its current and potential investors to read this quarterly report for information related to our third quarter 2019 financial results and other important corporate updates. A link to Melinta’s filings with the SEC can be found on its website at http://ir.melinta.com/financial-information/sec-filings.